Kim, Hyung-Don http://orcid.org/0000-0001-9959-0642
Jung, Seyoung http://orcid.org/0000-0002-0285-5972
Lim, Ho Yeong
Ryoo, Baek-Yeol http://orcid.org/0000-0002-9052-833X
Ryu, Min-Hee http://orcid.org/0000-0002-1033-1263
Chuah, Samuel http://orcid.org/0000-0002-7509-5126
Chon, Hong Jae
Kang, Beodeul http://orcid.org/0000-0001-5177-8937
Hong, Jung Yong
Lee, Han Chu http://orcid.org/0000-0002-7631-4124
Moon, Deok-Bog http://orcid.org/0000-0002-8209-3540
Kim, Ki-Hun
Kim, Tae Won
Tai, David
Chew, Valerie http://orcid.org/0000-0002-5617-0936
Lee, Jeong Seok
Finn, Richard S.
Koh, June-Young http://orcid.org/0000-0002-2043-6624
Yoo, Changhoon http://orcid.org/0000-0002-1451-8455
Funding for this research was provided by:
Bayer | Bayer CropScience (RENOBATE)
ONO Pharmaceuticals (grant reference number: RENOBATE) Genome Insight Inc. (grant reference number: RENOBATE) Korean Cancer Study Group
Korea Health Industry Development Institute (HI22C182600)
Article History
Received: 27 June 2023
Accepted: 21 January 2024
First Online: 19 February 2024
Competing interests
: C.Y. received honoraria from Servier, Bayer, AstraZeneca, Merck Sharp & Dohme, Eisai, Celgene, Bristol Myers Squibb, Ipsen, Novartis, Boryung Pharmaceuticals, Mundipharma and Roche and received research grants from Servier, Bayer, AstraZeneca, Ono Pharmaceuticals, Ipsen and Boryung Pharmaceuticals. H.-D.K. received honoraria from AstraZeneca, Bristol Myers Squibb, Ono Pharmaceuticals, Boryung Pharmaceuticals, Eisai, Daehwa and Boostimmune and served as a consultant for Mustbio. H.J.C. holds consulting or advisory roles with Eisai, Roche, Bayer, Ono Pharmaceuticals, Merck Sharp & Dohme, Bristol Myers Squibb, Sanofi, Servier, AstraZeneca, SillaJen, Menarini and GreenCross Cell and has received research grants from Roche, Dong-A ST and Boryung Pharmaceuticals. D.T. received honoraria from Novartis, Celgene, Sirtex, Merck Sharp & Dohme, Eisai, Ipsen, Bayer, GlaxoSmithKline, Roche and AstraZeneca and research support from Novartis, Sirtex and Bristol Myers Squibb. R.S.F. reports grants or contracts to institution from Adaptimmune, Bayer, Bristol Myers Squibb, Eisai, Eli Lilly, Pfizer, Roche and Genentech; personal consulting fees from Merck, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Cstone, Hengrui, Eisai, Eli Lilly, Merck Sharp & Dohme, Pfizer, Roche and Genentech; personal payments or honoraria from Genentech; and participation on a data safety monitoring or advisory board for AstraZeneca and Hengrui. All other authors have no competing interests to disclose.